search
Back to results

Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

Primary Purpose

Leukemia, Myelocytic, Acute, Acute Lymphocytic Leukemia

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
9-Aminocamptothecin (9-AC)
Sponsored by
Dana-Farber Cancer Institute
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia, Myelocytic, Acute focused on measuring leukemia, 9-Aminocamptothecin, AML, ALL, refractory leukemia, relapsed leukemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 18 years of age or older AML or ALL in first or subsequent relapse, secondary AML, or CML in blastic phase Central venous access ECOG performance status of less than or equal to 2 Bilirubin < 1.3 SGOT < 2 x ULN Alkaline phosphatase < 2 x ULN Creatinine < 1.5 Exclusion Criteria: Undergone bone marrow transplantation Uncontrolled infection Other active malignancy HIV positivity Serious medical or psychiatric illness Pregnancy

Sites / Locations

  • Massachusetts General Hosptial
  • Dana-Farber Cancer Institute

Outcomes

Primary Outcome Measures

To evaluate the toxicity and maximum tolerated dose of 9-AC administered as a 72 hour infusion in patients with relapsed/refractory leukemia.

Secondary Outcome Measures

To analyze the pharmacokinetics in these patients.

Full Information

First Posted
November 8, 2005
Last Updated
March 9, 2011
Sponsor
Dana-Farber Cancer Institute
Collaborators
Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00251368
Brief Title
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
Official Title
Multicenter Study of 9-AC in Refractory Leukemia
Study Type
Interventional

2. Study Status

Record Verification Date
March 2011
Overall Recruitment Status
Completed
Study Start Date
January 1995 (undefined)
Primary Completion Date
September 2007 (Actual)
Study Completion Date
September 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Dana-Farber Cancer Institute
Collaborators
Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and to determine the best dose which should be used to treat leukemia.
Detailed Description
The treatment patients will receive involves a continuous infusion of 9-AC intravenously for a 72 hour period. Since we are unsure of the safest and most effective dose, successive groups of 4-7 patients will receive larger doses of this drug until the largest dose given safely is established. Prior to the start of therapy a bone marrow aspirate and biopsy will be taken for diagnostic and research purposes. A bone marrow exam will be repeated at 48 hours in order to determine the effects of 9-AC on leukemic cells in the bone marrow. A bone marrow scan will also be performed 14 days after the start of therapy to assess response. Frequent blood testing will be done throughout treatment, including blood samples to determine the levels of the 9-AC in the blood. Treatment could be stopped prematurely if any of the following occur: 1) drug causes severe side effects, 2) the drug does not control the leukemia, or 3) the doctors or the patient feel that it is no longer in the patients best interest to receive this therapy. Approximately 7 days after the conclusion of the 9-AC infusion, it is likely that the patient's blood counts will be low and will require support with antibiotics, red cell transfusions and platelet transfusions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia, Myelocytic, Acute, Acute Lymphocytic Leukemia
Keywords
leukemia, 9-Aminocamptothecin, AML, ALL, refractory leukemia, relapsed leukemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
52 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
9-Aminocamptothecin (9-AC)
Primary Outcome Measure Information:
Title
To evaluate the toxicity and maximum tolerated dose of 9-AC administered as a 72 hour infusion in patients with relapsed/refractory leukemia.
Time Frame
Years
Secondary Outcome Measure Information:
Title
To analyze the pharmacokinetics in these patients.
Time Frame
years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years of age or older AML or ALL in first or subsequent relapse, secondary AML, or CML in blastic phase Central venous access ECOG performance status of less than or equal to 2 Bilirubin < 1.3 SGOT < 2 x ULN Alkaline phosphatase < 2 x ULN Creatinine < 1.5 Exclusion Criteria: Undergone bone marrow transplantation Uncontrolled infection Other active malignancy HIV positivity Serious medical or psychiatric illness Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Stone, MD
Organizational Affiliation
Dana-Farber Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hosptial
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

We'll reach out to this number within 24 hrs